The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection.
 
Melissa Amy Lumish
No Relationships to Disclose
 
Gowtham Jayakumaran
No Relationships to Disclose
 
Maggie Fox
No Relationships to Disclose
 
Shalom Sabwa
No Relationships to Disclose
 
Andrea Cercek
Consulting or Advisory Role - Array Biopharma; Bayer; Proteus Digital Health
Research Funding - Abbvie; Rgenix (Inst); Seagen; Tesaro
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Allergan (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Novartis (I); Optos (I); Regeneron (I); Regenxbio (I)
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); MedImmune (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals
 
Neil Howard Segal
Consulting or Advisory Role - ABL Bio; Aduro Biotech; Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; CStone Pharmaceuticals; GlaxoSmithKline; Gritstone Bio; Immunocore; Kyn therapeutics; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology
Research Funding - AstraZeneca; Bristol-Myers Squibb; Immunocore; Incyte; Merck; Pfizer; Roche/Genentech
 
Elizabeth Won
No Relationships to Disclose
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences
Honoraria - Clinical Care Options; MedEd; RMEI Medical Education
Consulting or Advisory Role - Basilea; Health Advances; Natera
Research Funding - Guardant Health (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Merck
 
Tiffany A. Troso-Sandoval
Honoraria - Bio Ascend
Travel, Accommodations, Expenses - Bio Ascend
 
Michal Fani Segal
No Relationships to Disclose
 
Vivian E. Strong
No Relationships to Disclose
 
Daniela Molena
Consulting or Advisory Role - Boston Scientific; Intuitive Surgical; Johnson & Johnson; Urogen pharma
 
Martin R. Weiser
Consulting or Advisory Role - Precisca
Research Funding - Clinical Genomics
 
David Randolph Jones
Stock and Other Ownership Interests - Diffusion Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Diffusion Pharmaceuticals; JuniperMD; Merck
 
Ahmet Zehir
Stock and Other Ownership Interests - Arcus Biosciences; Mirati Therapeutics
Honoraria - Illumina
 
Michael F. Berger
Research Funding - Grail
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Innovatus Capital Partners; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Imugene; Jounce Therapeutics; Lilly; Merck; Merck Serono; Merck Sharpe and Dohme Corp.; Michael J. Hennessy Associates; Ono Pharmaceutical; Pfizer; Rgenix; Seagen; Zymeworks
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Lilly; Merck; Rgenix (Inst); Roche
Other Relationship - Axis Medical Education; Clinical Care Options; Paradigm; Research to Practice